There were no differences in the distribution of thrombophilias between patients with and without MB on rivaroxaban, while in VKA patients prothrombin G20210A mutation was more frequent in subjects with MB as compared to those free of MB (Table 1). The gene discussed is F2; the disease is Rare hereditary thrombophilia.